Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.

Wagenlehner F, Nowicki M, Bentley C, Lückermann M, Wohlert S, Fischer C, Vente A, Naber K, Dalhoff A.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02317-17. doi: 10.1128/AAC.02317-17. Print 2018 Apr.

2.

Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections.

Taubert M, Lückermann M, Vente A, Dalhoff A, Fuhr U.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02328-17. doi: 10.1128/AAC.02328-17. Print 2018 Apr.

3.

Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates.

Vente A, Bentley C, Lückermann M, Tambyah P, Dalhoff A.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02325-17. doi: 10.1128/AAC.02325-17. Print 2018 Apr.

4.

Seventy-Five Years of Research on Protein Binding.

Dalhoff A.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01663-17. doi: 10.1128/AAC.01663-17. Print 2018 Feb. Review.

5.

Does the use of antifungal agents in agriculture and food foster polyene resistance development? A reason for concern.

Dalhoff A.

J Glob Antimicrob Resist. 2018 Jun;13:40-48. doi: 10.1016/j.jgar.2017.10.024. Epub 2017 Nov 7. Review.

PMID:
29127020
6.

Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.

Taubert M, Chiesa J, Lückermann M, Fischer C, Dalhoff A, Fuhr U.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01122-17. doi: 10.1128/AAC.01122-17. Print 2017 Oct.

7.
8.

Response to the reaction to Dalhoff and Levy: 'Does use of the polyene natamycin as a food preservative jeopardise the clinical efficacy of amphotericin B? A word of concern'.

Dalhoff A.

Int J Antimicrob Agents. 2015 Nov;46(5):596-7. doi: 10.1016/j.ijantimicag.2015.07.006. Epub 2015 Aug 15. No abstract available.

PMID:
26342242
9.

Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle.

Dalhoff A, Rashid MU, Kapsner T, Panagiotidis G, Weintraub A, Nord CE.

Clin Microbiol Infect. 2015 Aug;21(8):767.e1-4. doi: 10.1016/j.cmi.2015.05.025. Epub 2015 Jun 3.

10.

Does use of the polyene natamycin as a food preservative jeopardise the clinical efficacy of amphotericin B? A word of concern.

Dalhoff AA, Levy SB.

Int J Antimicrob Agents. 2015 Jun;45(6):564-7. doi: 10.1016/j.ijantimicag.2015.02.011. Epub 2015 Mar 21. Review.

11.

Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

Dalhoff A.

Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):661-8. doi: 10.1007/s10096-014-2296-3. Epub 2014 Dec 17. Review.

PMID:
25515946
12.
13.

Young children's agent-neutral representations of action roles.

Rakoczy H, Gräfenhain M, Clüver A, Dalhoff AC, Sternkopf A.

J Exp Child Psychol. 2014 Dec;128:201-9. doi: 10.1016/j.jecp.2014.06.004. Epub 2014 Jul 26.

PMID:
25074622
14.

In vitro activity of MCB3681 against Clostridium difficile strains.

Rashid MU, Dalhoff A, Weintraub A, Nord CE.

Anaerobe. 2014 Aug;28:216-9. doi: 10.1016/j.anaerobe.2014.07.001. Epub 2014 Jul 10.

PMID:
25016084
15.

Ecological impact of MCB3837 on the normal human microbiota.

Rashid MU, Dalhoff A, Bäckström T, Björkhem-Bergman L, Panagiotidis G, Weintraub A, Nord CE.

Int J Antimicrob Agents. 2014 Aug;44(2):125-30. doi: 10.1016/j.ijantimicag.2014.03.016. Epub 2014 May 23.

PMID:
24931053
16.

Alternative strategies for proof-of-principle studies of antibacterial agents.

Dalhoff A, Weintraub A, Nord CE.

Antimicrob Agents Chemother. 2014 Aug;58(8):4257-63. doi: 10.1128/AAC.02473-14. Epub 2014 May 27. Review.

17.

Evaluation of the effect of serum proteins on the antibacterial activity and pharmacodynamics of ceftaroline against Staphylococcus aureus.

Dalhoff A, Schubert S.

Int J Antimicrob Agents. 2013 Sep;42(3):285-7. doi: 10.1016/j.ijantimicag.2013.05.015. Epub 2013 Jul 26. No abstract available.

PMID:
23891526
18.

Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Dalhoff A.

Interdiscip Perspect Infect Dis. 2012;2012:976273. doi: 10.1155/2012/976273. Epub 2012 Oct 14.

20.

Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Dalhoff A.

Infection. 2012 Jun;40(3):239-62. doi: 10.1007/s15010-012-0257-2. Epub 2012 Mar 30. Review.

PMID:
22460782
21.

Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose.

Wagenlehner FM, Wagenlehner CM, Blenk B, Blenk H, Schubert S, Dalhoff A, Naber KG.

Chemotherapy. 2011;57(2):97-107. doi: 10.1159/000321028. Epub 2011 Feb 28.

PMID:
21358200
22.

Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine.

Dalhoff A, Stubbings W, Schubert S.

Antimicrob Agents Chemother. 2011 Apr;55(4):1814-8. doi: 10.1128/AAC.00886-10. Epub 2011 Jan 18.

23.

German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study.

Seifert H, Dalhoff A; PRISMA Study Group.

J Antimicrob Chemother. 2010 Nov;65(11):2405-10. doi: 10.1093/jac/dkq321. Epub 2010 Sep 16.

PMID:
20851813
24.

Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.

Dalhoff A, Schubert S.

Int J Antimicrob Agents. 2010 Sep;36(3):216-21. doi: 10.1016/j.ijantimicag.2010.04.014. Epub 2010 Jul 14.

PMID:
20630710
25.

A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

Dalhoff A, Ambrose PG, Mouton JW.

Infection. 2009 Aug;37(4):296-305. doi: 10.1007/s15010-009-7108-9. Epub 2009 Jul 23. Review.

PMID:
19629383
26.

Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).

Jacobs E, Dalhoff A, Korfmann G.

Int J Antimicrob Agents. 2009 Jan;33(1):52-7. doi: 10.1016/j.ijantimicag.2008.07.017. Epub 2008 Oct 1.

PMID:
18835763
27.

Immunomodulatory activities of fluoroquinolones.

Dalhoff A.

Infection. 2005 Dec;33 Suppl 2:55-70. Review.

PMID:
16518713
29.
30.
31.
32.

Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations.

Schubert S, Dalhoff A, Stass H, Ullmann U.

Infection. 2005 Dec;33 Suppl 2:15-21.

PMID:
16518707
34.

Redefining penems.

Dalhoff A, Janjic N, Echols R.

Biochem Pharmacol. 2006 Mar 30;71(7):1085-95. Epub 2006 Jan 18. Review.

PMID:
16413506
35.

Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.

Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Dalhoff A, Naber KG.

Int J Antimicrob Agents. 2006 Jan;27(1):7-14. Epub 2005 Dec 15.

PMID:
16343856
36.

Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.

Ulrich M, Albers C, Möller JG, Dalhoff A, Korfmann G, Künkele F, Döring G.

Antimicrob Agents Chemother. 2005 Dec;49(12):5119-22.

37.

In vitro activities of quinolones.

Dalhoff A.

Expert Opin Investig Drugs. 1999 Feb;8(2):123-37. No abstract available.

PMID:
15992068
38.

Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ.

Antimicrob Agents Chemother. 2004 Jun;48(6):2061-8.

39.

Towards targeted prescribing: will the cure for antimicrobial resistance be specific, directed therapy through improved diagnostic testing?

Peterson LR, Dalhoff A.

J Antimicrob Chemother. 2004 Jun;53(6):902-5. Epub 2004 Apr 29. Review.

PMID:
15117933
40.

Beta-lactamase stability of faropenem.

Dalhoff A, Nasu T, Okamoto K.

Chemotherapy. 2003 Sep;49(5):229-36.

PMID:
14504433
41.
42.

The art of fusion: from penams and cephems to penems.

Dalhoff A, Thomson CJ.

Chemotherapy. 2003 Jun;49(3):105-20. Review.

PMID:
12815203
43.

Immunomodulatory effects of quinolones.

Dalhoff A, Shalit I.

Lancet Infect Dis. 2003 Jun;3(6):359-71. Review.

PMID:
12781508
44.

In vitro antibacterial activity and pharmacodynamics of new quinolones.

Dalhoff A, Schmitz FJ.

Eur J Clin Microbiol Infect Dis. 2003 Apr;22(4):203-21. Epub 2003 Apr 1. Review.

PMID:
12687416
45.

Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance.

Schmitz FJ, Higgins PG, Mayer S, Fluit AC, Dalhoff A.

Eur J Clin Microbiol Infect Dis. 2002 Sep;21(9):647-59. Epub 2002 Sep 7. Review.

PMID:
12373497
46.

Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000.

Wagenlehner FM, Niemetz A, Dalhoff A, Naber KG.

Int J Antimicrob Agents. 2002 Jun;19(6):557-64.

PMID:
12135848
47.

Lack of interaction of fluoroquinolones with lipopolysaccharides.

Lindner B, Wiese A, Brandenburg K, Seydel U, Dalhoff A.

Antimicrob Agents Chemother. 2002 May;46(5):1568-70.

48.

Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.

Dalhoff A, Krasemann C, Wegener S, Tillotson G.

Clin Infect Dis. 2001 Mar 15;32 Suppl 1:S22-9. Review.

PMID:
11249825
49.
50.

Effects of amoxicillin, gentamicin, and moxifloxacin on the hemolytic activity of Staphylococcus aureus in vitro and in vivo.

Worlitzsch D, Kaygin H, Steinhuber A, Dalhoff A, Botzenhart K, Döring G.

Antimicrob Agents Chemother. 2001 Jan;45(1):196-202.

Supplemental Content

Loading ...
Support Center